ViaCyte Inc. is a leader in the emerging field of regenerative medicine. The company is developing novel cell replacement therapies as potential long-term diabetes treatments that will reduce or even eliminate the need for blood glucose monitoring, insulin administration, and the risks of hypoglycemia and diabetes-related complications. ViaCyte's goal is to create a product that can free patients with type 1 and type 2 diabetes from long-term insulin dependence. If successful, ViaCyte’s products will relieve patients of both the acute challenges and risks, as well as the long-term complications, associated with diabetes.